59212-11-2

Usage

Explanation

This is the chemical name of the compound, which is also known as diclofenac.

Explanation

Diclofenac belongs to a class of drugs called NSAIDs, which are commonly used to relieve pain, reduce inflammation, and treat fever.

Explanation

Diclofenac works by inhibiting the production of certain chemicals in the body that cause pain and inflammation.

Explanation

Diclofenac is often prescribed for various conditions, including arthritis, migraines, and menstrual cramps, to manage pain and inflammation.

Explanation

The drug is available in different forms, such as tablets, capsules, and a topical gel for local application, to suit different preferences and needs.

Explanation

Despite its effectiveness, diclofenac can have side effects, including gastrointestinal irritation, an increased risk of cardiovascular events, and potential liver and kidney problems.

Explanation

Due to the potential side effects, diclofenac should be used with caution and under the guidance of a healthcare professional to ensure safe and effective treatment.

Classification

Nonsteroidal anti-inflammatory drug (NSAID)

Mechanism of action

Inhibition of chemical production

Common uses

Arthritis, migraines, menstrual cramps

Available forms

Tablets, capsules, topical gel

Side effects

Gastrointestinal irritation, increased cardiovascular risk, liver/kidney problems

Precautions

Use with caution, under healthcare professional guidance

Upstream product

• 23023-16-7 2‐(3,4‐dimethoxyphenyl)‐2‐methylpropionitrile 
• 93-17-4 3,4-dimethoxyphenylacetonitrile 

Downstream Products

• 70822-02-5 2-(3,4-dimethoxy-phenyl)-2-methyl-propionic acid ethyl ester 
• 1239956-62-7 3-(2-chloro-6-fluorobenzylthio)-5-(2-(3,4-dimethoxyphenyl)propan-2-yl)-4-(4-fluorophenyl)-4H-1,2,4-triazole 
• 1239964-46-5 3-(2-(3,4-dimethoxyphenyl)propan-2-yl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5(4H)-thione 
• 1239964-44-3 2-(3,4-dimethoxyphenyl)-2-methylpropanehydrazide 
• 59212-12-3 2-(3,4-Dimethoxyphenyl)-2,N-dimethylpropionamid 
• 1017431-88-7 2-(3,4-Dimethoxy-phenyl)-2-methyl-propionyl chloride 

Relevant academic research and scientific papers

Cobalt-catalyzed C[sbnd]H activation/C[sbnd]O formation: Synthesis of benzofuranones

Herein, C[sbnd]H activation/C[sbnd]O formation reaction using novel cobalt catalytic system is reported. This reaction was given benzofuranones in moderate to excellent yields at room-temperature under air reaction conditions. The introduced strategy is efficient and low-cost method to synthesized benzofuranones from α,α-disubstitution acetic acid.

Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design

Alzheimer's disease (AD) is an incurable, progressive neurodegenerative disease whose pathogenesis cannot be defined by one single element but consists of various factors; thus, there is a call for alternative approaches to tackle the multifaceted aspects of AD. Among the potential alternative targets, we aim to focus on glutaminyl cyclase (QC), which reduces the toxic pyroform of β-amyloid in the brains of AD patients. On the basis of a putative active conformation of the prototype inhibitor 1, a series of N-substituted thiourea, urea, and α-substituted amide derivatives were developed. The structure-activity relationship analyses indicated that conformationally restrained inhibitors demonstrated much improved QC inhibition in vitro compared to nonrestricted analogues, and several selected compounds demonstrated desirable therapeutic activity in an AD mouse model. The conformational analysis of a representative inhibitor indicated that the inhibitor appeared to maintain the Z-E conformation at the active site, as it is critical for its potent activity.

Direct lactonization of 2-arylacetic acids through Pd(II)-catalyzed C-H activation/C-O formation

Palladium-catalyzed direct lactonization of 2-arylacetic acids through a reaction sequence that includes C-H activation/C-O formation is reported. This method provides a concise and efficient pathway to synthesize fully functionalized benzofuranone derivatives, which are highly relevant to bioactive natural and synthetic products.

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise